Home Cart 0 Sign in  

[ CAS No. 112885-41-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 112885-41-3
Chemical Structure| 112885-41-3
Structure of 112885-41-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 112885-41-3 ]

Related Doc. of [ 112885-41-3 ]

Alternatived Products of [ 112885-41-3 ]

Product Details of [ 112885-41-3 ]

CAS No. :112885-41-3 MDL No. :MFCD00867430
Formula : C21H25ClFN3O3 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 421.89 Pubchem ID :-
Synonyms :
TAK-370;AS-4370
Chemical Name :4-Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)morpholin-2-yl)methyl)benzamide

Calculated chemistry of [ 112885-41-3 ]

Physicochemical Properties

Num. heavy atoms : 29
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.38
Num. rotatable bonds : 8
Num. H-bond acceptors : 5.0
Num. H-bond donors : 2.0
Molar Refractivity : 114.41
TPSA : 76.82 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.88 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.52
Log Po/w (XLOGP3) : 2.81
Log Po/w (WLOGP) : 2.99
Log Po/w (MLOGP) : 2.31
Log Po/w (SILICOS-IT) : 3.68
Consensus Log Po/w : 3.06

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.0
Solubility : 0.0418 mg/ml ; 0.000099 mol/l
Class : Moderately soluble
Log S (Ali) : -4.08
Solubility : 0.0351 mg/ml ; 0.0000831 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -6.65
Solubility : 0.0000942 mg/ml ; 0.000000223 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.46

Safety of [ 112885-41-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 112885-41-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 112885-41-3 ]
  • Downstream synthetic route of [ 112885-41-3 ]

[ 112885-41-3 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 112885-41-3 ]
  • [ 112885-42-4 ]
YieldReaction ConditionsOperation in experiment
86% With citric acid In water at 0℃; Heating / reflux To the suspension of 1.3 g (2.5 [MMOL)] of compound [(VIII)] and 3 ml of water 12 m of [1 37percent] aqueous hydrochloric acid solution is added. The obtained solution is stirred at 40 [C] for 3 hours, cooled to 10 [C] and 38 mi of 4 M aqueous sodium hydroxide solution added dropwise. The precipitated mosapride base of formula IX is filtered, washed 2 x with water, to give 1.05 g (100percent) of the compound of formula [(IX).] 1.01 g of mosapride base of formula [(IX)] obtained the above manner is warmed to boiling with 25 [ML] of 10percent aqueous citric acid solution with stirring, cooled to 0 [C,] the precipitated product filtered, washed 2 x with water to give 1.34 g (86 percent) of the title compound. Mp: [110-113C.]
Reference: [1] Patent: WO2003/106440, 2003, A2, . Location in patent: Page 10
  • 2
  • [ 112885-41-3 ]
  • [ 77-92-9 ]
  • [ 112885-42-4 ]
YieldReaction ConditionsOperation in experiment
95.45% at 80 - 110℃; for 0.5 h; Citric acid monohydrate (84.67 g) and water (850 ml) were charged at ambient temperature and stirred to dissolve the solid. The reaction mass was heated up to 80°C and mosapride free base (85 g) was charged at 80°C. The heterogeneous mass was stirred and heated up to reflux (95 °C to 110°C). The clear solution was stirred at reflux temperature for 30 minutes. The reaction mass was cooled down to 0°C and was stirred at 0°C to 5°C for 30 minutes. The solid was filtered and washed with water (2 X 170 ml). The solid was suck dried and unloaded. The solid was dried at 60°C for 15 hours under vacuum to give the title compound.Yield: 125 g (95.45percent)Water content: 6.28percentD-II Impurity: 0.269
94.7% at 50℃; for 1 h; General procedure: Stirring blade, three-necked flask 100mL fitted with a thermometer, HPLC and thepurity 99.94percent of the amide compound 10.0g (23.8mmol) prepared in Preparation Example 1,ethanol 80g, and water 80g was added, stirring to obtain a slurry. The resulting slurry waswarmed to 50 ° C. Then, 13.6g citric acid (71.2mmol) was dropped to gradually the slurry overa period of (temperature 50 ° C of the aqueous solution) for 10 minutes aqueous solution ofcitric acid dissolved in water 20g, amide compound and citric acid was reacted (the temperatureof the reaction solution at the time of aqueous citric acid dropwise addition was adjusted to 50 °C (reaction temperature 50 ° C)). After the aqueous solution of citric acid dropping, and allowedto react for 1 hour at 50 ° C (reaction temperature 50 ° C. The reaction solution wasconfirmed by visual observation that became clear during this time. ). Thereafter, the resultantreaction solution was cooled slowly to 10 ° C, and held for 1 hour. The precipitated solid wasfiltered off by vacuum filtration and the cake was washed twice with water 30g. Obtained afterdrying under reduced pressure a white solid at an external temperature of 40 ° C, as a whitesolid 4-amino-5-chloro-2-ethoxy -N - [[4- (4-fluoro-benzyl) -2-morpholinyl] methyl] It wasobtained benzamide citrate 2 hydrate (citrate dihydrate) 14.1g (21.8mmol). Yield: 91.4percent, HPLCpurity: 99.94percent, by-products: (not detected) undetected, water content: 5.8percent, quantitative value:was 100.5percent. The results are shown in Table 1. Incidentally, the yield of citrate dihydrate is avalue obtained by measuring the mass of simply obtained solid.
Reference: [1] Patent: WO2011/107903, 2011, A1, . Location in patent: Page/Page column 11
[2] Patent: JP5743474, 2015, B2, . Location in patent: Paragraph 0065; 0069; 0071
  • 3
  • [ 636582-70-2 ]
  • [ 112885-41-3 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogenchloride In water at 40℃; for 3 h; Alkaline aqueous solution To the suspension of 1.3 g (2.5 [MMOL)] of compound [(VIII)] and 3 ml of water 12 m of [1 37percent] aqueous hydrochloric acid solution is added. The obtained solution is stirred at 40 [C] for 3 hours, cooled to 10 [C] and 38 mi of 4 M aqueous sodium hydroxide solution added dropwise. The precipitated mosapride base of formula IX is filtered, washed 2 x with water, to give 1.05 g (100percent) of the compound of formula [(IX).] 1.01 g of mosapride base of formula [(IX)] obtained the above manner is warmed to boiling with 25 [ML] of 10percent aqueous citric acid solution with stirring, cooled to 0 [C,] the precipitated product filtered, washed 2 x with water to give 1.34 g (86 percent) of the title compound. Mp: [110-113C.]
Reference: [1] Patent: WO2003/106440, 2003, A2, . Location in patent: Page 10
  • 4
  • [ 108282-38-8 ]
  • [ 112914-13-3 ]
  • [ 112885-41-3 ]
YieldReaction ConditionsOperation in experiment
67%
Stage #1: With benzyl chloroformate; triethylamine In dichloromethane at -5 - 0℃; for 3.66 h; Inert atmosphere
Stage #2: at -5 - 20℃; for 1.66 h; Inert atmosphere
Stirring blade, three-neckedflask 100mL fitted with a thermometer, a nitrogen atmosphere, were dissolved 4-amino-5-chloro-2-ethoxy-benzoic acid 50.0g (233.3mmol) in methylene chloride 1000 mL, triethylamine afterthe addition of 24.7g (243.3mmol), reaction of benzyl chloroformate 43.3g (243.3mol)temperature was added dropwise over a period as 40 minutes less than or equal to -5 ° C. Then,the mixture was stirred for 3 hours at 0 ° C. The reaction mixture obtained under a nitrogen atmosphere, to a 1000mL of methylene chloridesolution of 2 was cooled to below -5 ° C (aminomethyl) -4- (4-fluorobenzyl) morpholine 53.3g(233.3mmol) , the reaction temperature was added dropwise over 40 min to be equal to or lessthan -5 ° C. After stirring for 1 hour at room temperature, water 1000mL was added, followedby shaking with a separating funnel, the organic layer was separated. In addition, a 10 mass percentaqueous solution of sodium hydroxide 2000g In addition, the same procedure was carried out.The obtained organic layer was washed two times with ion-exchanged water 1500 mL, organiclayer was concentrated and the white solid was obtained 120.0 g. After the resulting white solid was dissolved by adding dimethylformamide 1157mL, water wasadded 267 ml. Gradually performed cooled to 5 ° C, held for 2 hours at 5 ° C, and theprecipitated crystals by filtration. The resulting white crystals were dried under reducedpressure, as a high-purity white crystalline 4-amino-5-chloro-2-ethoxy--N - [[4- (4-fluorobenzyl) -2-morpholinyl] methyl] benzamide (amide compound) was obtained 66.0g of the (156.3mmol).67.0percent yield, was HPLC purity 99.94percent.
Reference: [1] Patent: JP5743474, 2015, B2, . Location in patent: Paragraph 0062-0064
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
  • 5
  • [ 112913-96-9 ]
  • [ 112885-41-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
  • 6
  • [ 112885-42-4 ]
  • [ 112885-41-3 ]
Reference: [1] Patent: US2012/64162, 2012, A1,
[2] Patent: EP2433652, 2012, A1,
  • 7
  • [ 4093-28-1 ]
  • [ 112885-41-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
  • 8
  • [ 4235-43-2 ]
  • [ 112885-41-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
  • 9
  • [ 59-06-3 ]
  • [ 112885-41-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
  • 10
  • [ 112913-94-7 ]
  • [ 112885-41-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
  • 11
  • [ 131322-23-1 ]
  • [ 112885-41-3 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 2, p. 616 - 624
Same Skeleton Products
Historical Records

Similar Product of
[ 112885-41-3 ]

Chemical Structure| 112885-42-4

A101355[ 112885-42-4 ]

4-Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)morpholin-2-yl)methyl)benzamide 2-hydroxypropane-1,2,3-tricarboxylate

Reason: Free-salt